Search results
Moderna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine
Zacks via Yahoo Finance· 13 hours agoIt expects to generate around $4 billion in product revenues, driven mainly by the sales of its...
Moderna loses less than expected as Covid vaccine sales beat estimates, cost cuts take hold
CNBC· 2 weeks agoModerna on Thursday posted a narrower-than-expected loss for the first quarter as the company's...
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025...
Benzinga via Yahoo Finance· 2 weeks agoThursday, Moderna Inc (NASDAQ:MRNA) reported a first-quarter EPS loss of $(3.07), down from an...
Moderna beats estimates in Q1 2024, targets RSV vaccine launch in fall By Investing.com
Investing.com· 2 weeks agoModerna Inc. (NASDAQ:MRNA) reported first-quarter earnings and revenue that came ahead of analyst...
Moderna’s First Vaccine Was a Big Hit. Its Second Is a Let Down
Bloomberg via Yahoo Finance· 5 days ago(Bloomberg) -- Moderna Inc.’s pioneering Covid shot turned the company into a nearly $200 billion...
Moderna Announces Update on Investigational RSV Vaccine
Morningstar· 4 days ago(NASDAQ:MRNA) today announced it has been notified by the U.S. Food and Drug Administration (FDA) that due to administrative constraints, the agency does not expect...review ...
Moderna COVID vaccine sales plummet 91 percent - The Boston Globe
The Boston Globe· 2 weeks agoShares of Moderna rose more than 7 percent in early morning trading. Pfizer, the New York-based drug...
Moderna posts better-than-expected quarterly results as it looks to fall RSV vaccine launch
Market Watch· 2 weeks agoA Food and Drug Administration decision on approval of Moderna’s RSV vaccine is expected by May 12,...
Moderna expects CDC to view its RSV vaccine as equal to rival shots
Reuters· 2 weeks ago, opens new tab said on Thursday it expects U.S. Center for Disease Control and Prevention (CDC)...
Moderna plants new solid tumor trials for cancer vaccine, weeds PD-1 work after review
FierceBiotech· 2 weeks agoModerna detailed plans for its individual neoantigen cancer vaccine in a first-quarter earnings...